Limits...
Zaprinast and rolipram enhances spatial and emotional memory in the elevated plus maze and passive avoidance tests and diminishes exploratory activity in naive mice.

Akar F, Mutlu O, Komsuoglu Celikyurt I, Ulak G, Erden F, Bektas E, Tanyeri P - Med Sci Monit Basic Res (2014)

Bottom Line: Both zaprinast (10 mg/kg) and rolipram (0.1 mg/kg) significantly decreased the number of entries to new areas and time spent in new areas in the Hughes box test.Our study revealed that both zaprinast and rolipram enhanced spatial memory in EPM, while rolipram seemed to have more emotional memory-enhancing effects in the PA test compared to zaprinast.Both zaprinast and rolipram diminished exploratory activity in the Hughes box test, which can be attributed to the drugs' anxiogenic effects.

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmacology, Medical Faculty, Kocaeli University, Kocaeli, Turkey.

ABSTRACT

Background: Phosphodiesterase (PDE) inhibitors in the central nervous system have been shown to stimulate neuronal functions and increase neurogenesis in Alzheimer disease (AD) patients.

Material/methods: The aim of this study was to investigate the effects of zaprinast, a PDE5 inhibitor, and rolipram, a PDE4 inhibitor, on learning and memory in elevated plus maze (EPM) and passive avoidance (PA) tests in naive mice. Male Balb-c mice received short-term treatment with zaprinast (3 and 10 mg/kg) and rolipram (0.05 and 0.1 mg/kg) before the acquisition trial of the EPM and PA tests. The exploratory activity of the animals was also investigated in the Hughes box test.

Results: Both zaprinast (10 mg/kg) and rolipram (0.1 mg/kg) significantly decreased second-day latency compared to the control group in the EPM test, while only rolipram (0.1 mg/kg) significantly increased second-day latency in the PA test. Both zaprinast (10 mg/kg) and rolipram (0.1 mg/kg) significantly decreased the number of entries to new areas and time spent in new areas in the Hughes box test.

Conclusions: Our study revealed that both zaprinast and rolipram enhanced spatial memory in EPM, while rolipram seemed to have more emotional memory-enhancing effects in the PA test compared to zaprinast. Both zaprinast and rolipram diminished exploratory activity in the Hughes box test, which can be attributed to the drugs' anxiogenic effects.

Show MeSH

Related in: MedlinePlus

Effect of zaprinast (3 and 10 mg/kg) and rolipram (0.05 and 0.1 mg/kg) on learning and memory (n=6) (in which zaprinast and rolipram was administered 60 and 30 min; respectively before the training) in the elevated plus maze test in mice. The data are expressed as mean ±SEM values of animals. # p<0.05, when the first and second sessions of groups were compared; * p<0.05, ** p<0.01 compared to second session of the control group.
© Copyright Policy
Related In: Results  -  Collection


getmorefigures.php?uid=PMC4117679&req=5

f1-medscimonitbasicres-20-105: Effect of zaprinast (3 and 10 mg/kg) and rolipram (0.05 and 0.1 mg/kg) on learning and memory (n=6) (in which zaprinast and rolipram was administered 60 and 30 min; respectively before the training) in the elevated plus maze test in mice. The data are expressed as mean ±SEM values of animals. # p<0.05, when the first and second sessions of groups were compared; * p<0.05, ** p<0.01 compared to second session of the control group.

Mentions: When zaprinast (3 and 10 mg/kg) and rolipram (0.05 and 0.01 mg/kg) were administered before the acquisition session (training; Day 1), there was no significant difference in first-day latency (TL1) among the groups (H=7.12; p=0.12, Figure 1). Zaprinast (10 mg/kg) and rolipram (0.1 mg/kg) significantly shortened latency (TL2) on the second day compared to the control group when the drug was administered before the acquisition session (Kruskal-Wallis H=16.36; p<0.05 and p<0.01, respectively) (Figure 1). In the comparison of TL1 and TL2 for each drug-treated group, TL2 was significantly decreased in the control, zaprinast 10 mg/kg and rolipram (0.05 and 0.1 mg/kg) groups (p<0.05), but this measure was not significantly different between the zaprinast 3 mg/kg groups (p>0.05) (Figure 1).


Zaprinast and rolipram enhances spatial and emotional memory in the elevated plus maze and passive avoidance tests and diminishes exploratory activity in naive mice.

Akar F, Mutlu O, Komsuoglu Celikyurt I, Ulak G, Erden F, Bektas E, Tanyeri P - Med Sci Monit Basic Res (2014)

Effect of zaprinast (3 and 10 mg/kg) and rolipram (0.05 and 0.1 mg/kg) on learning and memory (n=6) (in which zaprinast and rolipram was administered 60 and 30 min; respectively before the training) in the elevated plus maze test in mice. The data are expressed as mean ±SEM values of animals. # p<0.05, when the first and second sessions of groups were compared; * p<0.05, ** p<0.01 compared to second session of the control group.
© Copyright Policy
Related In: Results  -  Collection

Show All Figures
getmorefigures.php?uid=PMC4117679&req=5

f1-medscimonitbasicres-20-105: Effect of zaprinast (3 and 10 mg/kg) and rolipram (0.05 and 0.1 mg/kg) on learning and memory (n=6) (in which zaprinast and rolipram was administered 60 and 30 min; respectively before the training) in the elevated plus maze test in mice. The data are expressed as mean ±SEM values of animals. # p<0.05, when the first and second sessions of groups were compared; * p<0.05, ** p<0.01 compared to second session of the control group.
Mentions: When zaprinast (3 and 10 mg/kg) and rolipram (0.05 and 0.01 mg/kg) were administered before the acquisition session (training; Day 1), there was no significant difference in first-day latency (TL1) among the groups (H=7.12; p=0.12, Figure 1). Zaprinast (10 mg/kg) and rolipram (0.1 mg/kg) significantly shortened latency (TL2) on the second day compared to the control group when the drug was administered before the acquisition session (Kruskal-Wallis H=16.36; p<0.05 and p<0.01, respectively) (Figure 1). In the comparison of TL1 and TL2 for each drug-treated group, TL2 was significantly decreased in the control, zaprinast 10 mg/kg and rolipram (0.05 and 0.1 mg/kg) groups (p<0.05), but this measure was not significantly different between the zaprinast 3 mg/kg groups (p>0.05) (Figure 1).

Bottom Line: Both zaprinast (10 mg/kg) and rolipram (0.1 mg/kg) significantly decreased the number of entries to new areas and time spent in new areas in the Hughes box test.Our study revealed that both zaprinast and rolipram enhanced spatial memory in EPM, while rolipram seemed to have more emotional memory-enhancing effects in the PA test compared to zaprinast.Both zaprinast and rolipram diminished exploratory activity in the Hughes box test, which can be attributed to the drugs' anxiogenic effects.

View Article: PubMed Central - PubMed

Affiliation: Department of Pharmacology, Medical Faculty, Kocaeli University, Kocaeli, Turkey.

ABSTRACT

Background: Phosphodiesterase (PDE) inhibitors in the central nervous system have been shown to stimulate neuronal functions and increase neurogenesis in Alzheimer disease (AD) patients.

Material/methods: The aim of this study was to investigate the effects of zaprinast, a PDE5 inhibitor, and rolipram, a PDE4 inhibitor, on learning and memory in elevated plus maze (EPM) and passive avoidance (PA) tests in naive mice. Male Balb-c mice received short-term treatment with zaprinast (3 and 10 mg/kg) and rolipram (0.05 and 0.1 mg/kg) before the acquisition trial of the EPM and PA tests. The exploratory activity of the animals was also investigated in the Hughes box test.

Results: Both zaprinast (10 mg/kg) and rolipram (0.1 mg/kg) significantly decreased second-day latency compared to the control group in the EPM test, while only rolipram (0.1 mg/kg) significantly increased second-day latency in the PA test. Both zaprinast (10 mg/kg) and rolipram (0.1 mg/kg) significantly decreased the number of entries to new areas and time spent in new areas in the Hughes box test.

Conclusions: Our study revealed that both zaprinast and rolipram enhanced spatial memory in EPM, while rolipram seemed to have more emotional memory-enhancing effects in the PA test compared to zaprinast. Both zaprinast and rolipram diminished exploratory activity in the Hughes box test, which can be attributed to the drugs' anxiogenic effects.

Show MeSH
Related in: MedlinePlus